Zacks: Brokerages Anticipate Senesco Technologies Inc. (NYSE:ELOX) Will Announce Earnings of -$0.39 Per Share

Wall Street brokerages expect that Senesco Technologies Inc. (NYSE:ELOX) will announce ($0.39) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Senesco Technologies’ earnings. The lowest EPS estimate is ($0.44) and the highest is ($0.36). Senesco Technologies posted earnings per share of ($0.32) during the same quarter last year, which would indicate a negative year over year growth rate of 21.9%. The company is scheduled to announce its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Senesco Technologies will report full year earnings of ($1.51) per share for the current year, with EPS estimates ranging from ($1.65) to ($1.41). For the next financial year, analysts anticipate that the business will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.62) to ($1.45). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Senesco Technologies.

Senesco Technologies (NYSE:ELOX) last released its earnings results on Wednesday, August 7th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03).

Senesco Technologies stock traded up $0.06 during midday trading on Tuesday, reaching $6.24. The company’s stock had a trading volume of 31,600 shares, compared to its average volume of 54,511. Senesco Technologies has a fifty-two week low of $5.14 and a fifty-two week high of $18.50. The stock’s 50 day simple moving average is $8.30 and its 200 day simple moving average is $10.51.

About Senesco Technologies

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Recommended Story: What does the Producer Price Index (PPI) tell investors?

Get a free copy of the Zacks research report on Senesco Technologies (ELOX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Senesco Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies and related companies with's FREE daily email newsletter.